PTC Therapeutics (FRA:BH3) Institutional Ownership: 73.60% (As of Aug. 05, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:BH3 PTC Therapeutics Inc FRA:BH3
53 GF Score
Price €58.54
GF Value €31.98
! 7 Warning Signs
View Full Analysis

What is PTC Therapeutics Institutional Ownership?

PTC Therapeutics FRA:BH3 +0.14% 53 Institutional Ownership is 73.60% as of Aug. 05, 2026. GuruFocus rates FRA:BH3 with a GF Score™ of 53/100 and a GF Value™ of €31.98. The stock has 7 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, PTC Therapeutics's institutional ownership is 73.60%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, PTC Therapeutics's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, PTC Therapeutics's Float Percentage Of Total Shares Outstanding is 73.77%.

PTC Therapeutics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for PTC Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PTC Therapeutics Institutional Ownership Chart

PTC Therapeutics Historical Data

The historical data trend for PTC Therapeutics can be seen below:

2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30 2026-07-31
Institutional Ownership 53.99 65.54 63.81 64.49 65.43 67.60 66.41 67.62 73.34 73.60
FRA:BH3
53GF Score
PTC Therapeutics Inc FRA:BH3
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PTC Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 73.60% mean?
PTC Therapeutics (FRA:BH3) has a Institutional Ownership of 73.60% as of Aug. 05, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on PTC Therapeutics and its competitors.
Is PTC Therapeutics' Institutional Ownership too high?
PTC Therapeutics' current Institutional Ownership is 73.60%. Overall, PTC Therapeutics has a GF Score™ of 53/100, reflecting its overall financial health beyond just this single metric.
How does PTC Therapeutics' Institutional Ownership compare to XENE and CGON?
PTC Therapeutics' Institutional Ownership of 73.60% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on PTC Therapeutics and its competitors. PTC Therapeutics's current Institutional Ownership is 73.60%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PTC Therapeutics stock overvalued right now?
PTC Therapeutics (FRA:BH3) has a current Institutional Ownership of 73.60%. The stock's GF Value™ is €31.98, compared to a current price of €58.54 — trading 83.1% above its estimated fair value. The current Institutional Ownership is 73.60%. PTC Therapeutics' overall GF Score™ is 53/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For PTC Therapeutics (FRA:BH3), the current Institutional Ownership is 73.60% as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PTC Therapeutics (FRA:BH3) Overvalued in 2026?

Based on GuruFocus' analysis, PTC Therapeutics stock appears to be overvalued. The current stock price of €58.54 is trading 83.1% above its estimated GF Value™ of €31.98.

Key valuation signals for FRA:BH3:

  • Institutional Ownership: 73.60%
  • GF Value™: €31.98 vs. price of €58.54 (83.1% above fair value)
  • GF Score™: 53/100 with 7 warning signs

No single metric tells the full story. See the FRA:BH3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PTC Therapeutics Business Description

Other Exchanges PTCT:USABH3:Germany
Address 500 Warren Corporate Center Drive, Warren, NJ, USA, 07059
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
53GF Score

Get the complete analysis for FRA:BH3

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€58.54
Price
€31.98
GF Value